Vivian Chih-Wei Chen

Dr. Vivian Chih-Wei Chen

Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Central Singapore, Singapore
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
CTChee Wah Tan
Chee Wah Tan
WCWan Ni Chia
Wan Ni Chia
XQXijian Qin
Xijian Qin
PLPei Liu
Pei Liu
MCMark I.-C. Chen
Mark I.-C. Chen
LWLin-Fa Wang
Lin-Fa Wang
A robust serological test to detect neutralizing antibodies to SARS-CoV-2 is urgently needed to determine not only the infection rate, herd immunity and predicted humoral protection, but also vaccine efficacy during clinical trials and after large-scale vaccination. The current gold standard is the conventional virus neutralization test requiring live pathogen and a biosafety level 3 laboratory. Here, we report a SARS-CoV-2 surrogate virus neutralization test that detects total immunodominant neutralizing antibodies targeting the viral spike (S) protein receptor-binding domain in an isotype- and species-independent manner. Our simple and rapid test is based on antibody-mediated blockage of the interaction between the angiotensin-converting enzyme 2 (ACE2) receptor protein and the receptor-binding domain. The test, which has been validated with two cohorts of patients with COVID-19 in two different countries, achieves 99.93% specificity and 95–100% sensitivity, and differentiates antibody responses to several human coronaviruses. The surrogate virus neutralization test does not require biosafety level 3 containment, making it broadly accessible to the wider community for both research and clinical applications.

9 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SWSupaporn Wacharapluesadee
Supaporn Wacharapluesadee
CTChee Wah Tan
Chee Wah Tan
PMPatarapol Maneeorn
Patarapol Maneeorn
PDPrateep Duengkae
Prateep Duengkae
FZFeng Zhu
Feng Zhu
LWLin-Fa Wang
Lin-Fa Wang
Among the many questions unanswered for the COVID-19 pandemic are the origin of SARS-CoV-2 and the potential role of intermediate animal host(s) in the early animal-to-human transmission. The discovery of RaTG13 bat coronavirus in China suggested a high probability of a bat origin. Here we report molecular and serological evidence of SARS-CoV-2 related coronaviruses (SC2r-CoVs) actively circulating in bats in Southeast Asia. Whole genome sequences were obtained from five independent bats (Rhinolophus acuminatus) in a Thai cave yielding a single isolate (named RacCS203) which is most related to the RmYN02 isolate found in Rhinolophus malayanus in Yunnan, China. SARS-CoV-2 neutralizing antibodies were also detected in bats of the same colony and in a pangolin at a wildlife checkpoint in Southern Thailand. Antisera raised against the receptor binding domain (RBD) of RmYN02 was able to cross-neutralize SARS-CoV-2 despite the fact that the RBD of RacCS203 or RmYN02 failed to bind ACE2. Although the origin of the virus remains unresolved, our study extended the geographic distribution of genetically diverse SC2r-CoVs from Japan and China to Thailand over a 4800-km range. Cross-border surveillance is urgently needed to find the immediate progenitor virus of SARS-CoV-2.

4 October 2022 in Nature Microbiology
Verified
Journal Article
Open access
PDF file
CTChee Wah Tan
Chee Wah Tan
WCWan Ni Chia
Wan Ni Chia
FZFeng Zhu
Feng Zhu
BYBarnaby Young
Barnaby Young
NCNapaporn Chantasrisawad
Napaporn Chantasrisawad
LWLin-Fa Wang
Lin-Fa Wang
The SARS-CoV-2 Omicron variant (B.1.1.529 lineage) escapes antibodies that neutralize the ancestral virus. We tested human serum panels from participants with differing infection and vaccination status using a multiplex surrogate virus neutralization assay targeting 20 sarbecoviruses. We found that bat and pangolin sarbecoviruses showed significantly less neutralization escape than the Omicron variant. We propose that SARS-CoV-2 variants have emerged under immune selection pressure and are evolving differently from animal sarbecoviruses.

25 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SWSupaporn Wacharapluesadee
Supaporn Wacharapluesadee
CTChee Wah Tan
Chee Wah Tan
PMPatarapol Maneeorn
Patarapol Maneeorn
PDPrateep Duengkae
Prateep Duengkae
FZFeng Zhu
Feng Zhu
LWLin-Fa Wang
Lin-Fa Wang
A Correction to this paper has been published: https://doi.org/10.1038/s41467-021-21768-2

23 February 2022 in Research Square
Verified
Preprint
Open access
PDF file
LWLin-Fa Wang
Lin-Fa Wang
CTChee Wah Tan
Chee Wah Tan
WCWan Ni Chia
Wan Ni Chia
FZFeng Zhu
Feng Zhu
BYBarnaby Young
Barnaby Young
DLDavid Lye
David Lye
The SARS-CoV-2 B.1.1.529 lineage, Omicron variant, was first detected in November 2021 and carries 32 amino acid mutations in the spike protein (15 in RBD) and exhibits significant escape of neutralizing antibodies targeting the parental SARS-CoV-2 virus. Here, we performed a high-resolution multiplex (16-plex) surrogate virus neutralization assay covering all major SARS-CoV-2 variants and pre-emergent ACE2-binding sarbecoviruses against 20 different human serum panels from infected, vaccinated and hybrid immune individuals which had vaccine-breakthrough infections or infection followed by vaccination. Among all sarbecoviruses tested, we observed 1.1 to 4.7-, 2.3 to 10.3- and 0.7 to 33.3-fold reduction in neutralization activities to SARS-CoV-2 Beta, Omicron and SARS-CoV-1, respectively. Among the SARS-CoV-2 related sarbecoviruses, it is found that the genetically more distant bat RaTG13 and pangolin GX-P5L sarbecoviruses had less neutralization escape than Omicron. Our data suggest that the SARS-CoV-2 variants emerged from the changed immune landscape of human populations are more potent in escaping neutralizing antibodies, from infection or vaccination, than pre-emergent sarbecoviruses naturally evolved in animal populations with no or less immune selection pressure.

21 October 2024 in Viruses
Verified
Journal Article
Open access
PDF file
VCVivian Chih-Wei Chen
Vivian Chih-Wei Chen
CJCraig Ryan Joseph
Craig Ryan Joseph
WCWharton O.Y. Chan
Wharton O.Y. Chan
WSWan Rong Sia
Wan Rong Sia
QSQi Su
Qi Su
WCWan Cheng Chow
Wan Cheng Chow
Inflammasome is linked to many inflammatory diseases, including COVID-19 and autoimmune liver diseases. While severe COVID-19 was reported to exacerbate liver failure, we report a fatal acute-on-chronic liver failure (ACLF) in a stable primary biliary cholangitis-autoimmune hepatitis overlap syndrome patient triggered by a mild COVID-19 infection. Postmortem liver biopsy showed sparse SARS-CoV-2-infected macrophages with extensive ASC (apoptosis-associated speck-like protein containing a CARD) speck-positive hepatocytes, correlating with elevated circulating ASC specks and inflammatory cytokines, and depleted blood monocyte subsets, indicating widespread liver inflammasome activation. This first report of a fatal inflammatory cascade in an autoimmune liver disease triggered by a mild remote viral infection hopes to elucidate a less-described pathophysiology of ACLF that could prompt consideration of new diagnostic and therapeutic options.